Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Apr;100(4):384-8.
doi: 10.1016/S1081-1206(10)60603-5.

Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial

Joelle O'Neil  1 , Susan Hughes, Andrea Lourie, John Zweifler
Affiliations
Randomized Controlled Trial

Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial

Joelle O'Neil et al. Ann Allergy Asthma Immunol. 2008 Apr.

Abstract

Background: Upper respiratory tract infection symptoms are a common cause of morbidity. Herbal preparations of the plant Echinacea purpurea have immune-enhancing properties.

Objective: To compare the frequency of upper respiratory tract symptoms in individuals receiving E. purpurea capsules and those receiving placebo to evaluate the preventive efficacy of echinacea.

Methods: In a randomized, double-blind clinical trial, 90 volunteers recruited from hospital personnel were randomly assigned to receive 3 capsules twice daily of either placebo (parsley) or E. purpurea for 8 weeks during the winter months. Upper respiratory tract symptoms were reported weekly during this period.

Results: Fifty-eight individuals were included in the final data analysis: 28 in the echinacea group and 30 in the placebo group. Individuals in the echinacea group reported 9 sick days per person during the 8-week period, whereas the placebo group reported 14 sick days (z = -0.42; P = .67). Mild adverse effects were noted by 8% of the echinacea group and 7% of the placebo group (P = .24).

Conclusion: Prophylactic treatment with commercially available E. purpurea capsules did not significantly alter the frequency of upper respiratory tract symptoms compared with placebo use.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Randomization and participation results.
Figure 2
Figure 2
Participants with any respiratory problems.
See this image and copyright information in PMC

References

    1. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med. 1996;125:81–88. - PubMed
    1. Gwaltney JM, Jr, Hendley JO, Simon G, Jordan WS., Jr Rhinovirus infections in an industrial population, I: the occurrence of illness. N Engl J Med. 1966;275:1261–1268. - PubMed
    1. Sun LZ, Currier NL, Miller SC. The American coneflower: a prophylactic role involving nonspecific immunity. J Altern Complement Med. 1999;5:437–446. - PubMed
    1. Wustenberg P, Henneicke-von Zepelin HH, Kohler G, Stammwitz U. Efficacy and mode of action of an immunomodulator herbal preparation containing Echinacea, wild indigo, and white cedar. Adv Ther. 1999;16:51–70. - PubMed
    1. Percival SS. Use of echinacea in medicine. Biochem Pharmacol. 2000;60:155–158. - PubMed

Publication types

Substances